Global Genome Editing/Genome Engineering Market is projected to be worth USD 25.3 billion by 2030
According to SPER Market Research, the Genome Editing/Genome Engineering Market is estimated to reach USD 25.3 billion by 2030 with a CAGR of 19.5%. Academies & government research centre used genome engineering before, now it is diversified into clinical & diagnostic fields too, this leads to the escalation of the market.
Impact of COVID-19 on the Genome Editing/Genome Engineering Market
The outbreak of COVID-19 has boosted the investment of pharmaceutical companies and biopharmaceutical companies, and genomic market player in research & development and in vaccine.
Scope of the report:
Market size available for years
2019-2030
Base year considered
2021
Forecast period
2022-2030
Segments covered
By Product & Service, By Application, By Technology, By End Users, By Region
Geographies covered
North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered
Agilent Technologies, Beam Therapeutics, Bluebird Bio, Caribou Biosciences., Cellectis S.A, Creative Biogene, CRISPR Therapeutics AG, Editas Medicine, GenScript, Integrated DNA Technologies, Intellia Therapeutics, Lonza, Merck KGaA, New England Biolabs, OriGene Technologies, PerkinElmer, Precision Biosciences, Recombinetics, Regeneron Pharmaceuticals, Sangamo Therapeutics, Synthego, Tecan Life Sciences, Thermo Fisher Scientific, Transposagen, Biopharmaceuticals, Vigene Biosciences
Driver: Increase in funding
In the recent years there is increase in the government funding globally in the genomic research this allows academies & research centre to work on genomic engineering.
Restraints: Off-target effect of CRISPR Technology
CRISPR-Cas9 has an Off-target effects, The mismatch tolerance capacity of CRISPR-Cas9 is one to three, beyond this leads to off-target nuclease activity; it can be the reason for mutations in these genes in turn oncogenesis.
Opportunity: widespread use of Genome Engineering
Due to better efficacy, compliance, economical, optimization of therapy the demand for personalized medicine increasing worldwide. Personalized medicine markets offering lots of opportunities to the genomic market.
Challenges: Costly equipment
At the beginning, this might be costly for the academic research to afford, but in later stage the advanced technology is going to build affordable instruments, so it is a short term challenges for this market.
Global Genome Editing/Genome Engineering Market, by Product & Service: Based on the Product & Service, Global Genome Editing/Genome Engineering Market is segmented as; Reagents & consumables, Services, Software & systems
Global Genome Editing/Genome Engineering Market, by Application:
Based on the Application, Global Genome Editing/Genome Engineering Market is segmented as; Cell Line Engineering, Diagnostic applications, Drug discovery & development, Genetic Engineering, Other applications
Global Genome Editing/Genome Engineering Market, by Technology:
Based on the Technology, Global Genome Editing/Genome Engineering Market is segmented as; Antisense, CRISPR, TALEN, ZFN, Other technologies.
Global Genome Editing/Genome Engineering Market, by End-Users:
Based on the End-Users, Global Genome Editing/Genome Engineering Market is segmented as; Academic & Government Research Institutes, Biotechnology companies, Pharmaceutical companies.
Global Genome Editing/Genome Engineering Market, by Region:
North America owns the prime share of this market; it is because of growing exploitation of genetically modified crops, gene therapy, government grants and funding.
'
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. COVID-19 Impact on the Genome Editing/Genome Engineering Market
4.4. Market Trends
5. Global Genome Editing/Genome Engineering Market, by Product & Service, 2019-2030 (USD Million)
5.1. Reagents & consumables
5.2. Services
5.3. Software & systems
6. Global Genome Editing/Genome Engineering Market, by Application, 2019-2030 (USD Million)
6.1. Cell Line Engineering
6.2. Diagnostic applications
6.3. Drug discovery & development
6.4. Genetic Engineering
6.5. Other applications
7. Global Genome Editing/Genome Engineering Market, by Technology, 2019-2030 (USD Million)
7.1. Antisense
7.2. CRISPR
7.3. TALEN
7.4. ZFN
7.5. Other technologies
8. Global Genome Editing/Genome Engineering Market, by End-Users, 2019-2030 (USD Million)
8.1. Academic & Government Research Institutes
8.2. Biotechnology companies
8.3. Pharmaceutical companies
9. Global Genome Editing/Genome Engineering Market, by Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. France
9.2.2. Germany
9.2.3. Italy
9.2.4. Spain
9.2.5. UK
9.2.6. Rest of the Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Rest of Asia Pacific
9.4. Latin America
9.5. Middle East
9.6. Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis, By Key Players
10.3. Competitive Scenario
10.3.1. Product Launches
10.3.2. Partnerships, Collaborations and Agreements
10.3.3. Acquisitions
10.3.4. Expansions
10.3.5. Other Developments
11. Company Profiles
11.1. Agilent Technologies
11.2. Beam Therapeutics
11.3. Bluebird Bio
11.4. Caribou Biosciences.
11.5. Cellectis S.A
11.6. Creative Biogene
11.7. CRISPR Therapeutics AG
11.8. Editas Medicine
11.9. GenScript
11.10. Integrated DNA Technologies
11.11. Intellia Therapeutics
11.12. Lonza
11.13. Merck KGaA
11.14. New England Biolabs
11.15. OriGene Technologies
11.16. PerkinElmer
11.17. Precision Biosciences
11.18. Recombinetics
11.19. Regeneron Pharmaceuticals
11.20. Sangamo Therapeutics
11.21. Synthego
11.22. Tecan Life Sciences
11.23. Thermo Fisher Scientific
11.24. Transposagen Biopharmaceuticals
11.25. Vigene Biosciences
12. Appendix
11. Company Profiles
11.1. Agilent Technologies
11.2. Beam Therapeutics
11.3. Bluebird Bio
11.4. Caribou Biosciences.
11.5. Cellectis S.A
11.6. Creative Biogene
11.7. CRISPR Therapeutics AG
11.8. Editas Medicine
11.9. GenScript
11.10. Integrated DNA Technologies
11.11. Intellia Therapeutics
11.12. Lonza
11.13. Merck KGaA
11.14. New England Biolabs
11.15. OriGene Technologies
11.16. PerkinElmer
11.17. Precision Biosciences
11.18. Recombinetics
11.19. Regeneron Pharmaceuticals
11.20. Sangamo Therapeutics
11.21. Synthego
11.22. Tecan Life Sciences
11.23. Thermo Fisher Scientific
11.24. Transposagen Biopharmaceuticals
11.25. Vigene Biosciences
